AMERICAN DIAGNOSTICA INC. – Trademark Portfolio
Entity Type: 03
AMERICAN DIAGNOSTICA INC. holds 17 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 15 filings in this category. The portfolio also extends into Class 1 (Chemicals) across 3 Nice Classification classes. Currently, 7 trademarks are registered. Notable registered marks include DVVTEST, IMUBIND, ACTICLOT, DIMERTEST, and ACTICHROME. The owner is based in STAMFORD, CT.
500 WEST AVENUE
STAMFORD, CT 06902
Showing of trademarks Trademarks
Trademark Classifications
AMERICAN DIAGNOSTICA INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Frequently Asked Questions
How many trademarks does AMERICAN DIAGNOSTICA INC. have?
AMERICAN DIAGNOSTICA INC. has 17 U.S. trademarks filed with the USPTO. Of these, 7 registered, 1 abandoned, 9 cancelled.
What trademark classes does AMERICAN DIAGNOSTICA INC. file in?
AMERICAN DIAGNOSTICA INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 1 (Chemicals), Class 10 (Medical Apparatus). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are AMERICAN DIAGNOSTICA INC.'s most well-known trademarks?
AMERICAN DIAGNOSTICA INC.'s registered trademark portfolio includes well-known marks such as DVVTEST, IMUBIND, ACTICLOT, DIMERTEST, and ACTICHROME. These are among 7 currently registered trademarks in the portfolio.
What is AMERICAN DIAGNOSTICA INC.'s trademark registration success rate?
AMERICAN DIAGNOSTICA INC. has a 41% trademark registration rate, with 7 out of 17 resolved applications resulting in successful registration. Currently, 0 applications are pending review.